- February 18, 2021
Nadine J. Barrett, PhD., MA., MS - Assistant Professor, Department of Family Medicine and Community Health, Duke School of Medicine
‘Lola Fashoyin-Aje, MD, MPH - Deputy Division Director (Acting), Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA & Associate Director of Scientific and Policy Initiatives to Address Disparities in Drug Development, Oncology Center of Excellence, FDA
Mel Mann, MBA, M.Ed. - National Community Outreach Coordinator, Leukemia and Lymphoma Society, Myeloma Link Program – Chronic Myeloid Leukemia Survivor & Patient Advocate Promoting Clinical Trial Participation
Lori Pierce, MD - President, American Society of Clinical Oncology
Lori Wilson, MD - Howard University Hospital Surgical Oncologist and Cancer Survivor
Robert Winn, MD - Director, NCI-designated Massey Cancer Center, Virginia Commonwealth University
Rea Blakey, Associate Director of External Outreach and Engagement, Oncology Center of Excellence, FDA
Does a Black cancer patient have equal access to clinical trial participation? How is a patient’s cancer treatment and chance of survival different if they are a Black American? What actions can we each take to contribute to greater equity in the treatment of all Americans with cancer? Be sure to join this lively Oncology Center of Excellence panel discussion.
This 1.5-hour conversation revisits the panel discussion held in July 2020 by further exploring the experiences of Black patients, healthcare researchers, and healthcare providers in the oncology space, along with discussion regarding obstacles for inclusion in cancer clinical trials and efforts to achieve health equity.
A free-of-charge webcast of this workshop will be provided. Registration for the webcast is required at the link above. The link for the webcast will be provided to all registered no less than 24 hours prior to the start of the workshop.
FDA plans to post archived webcasts after the meeting, however, in cases where the transmission was not successful, archived webcasts will not be available.
For additional information, please send an email to: OCE-Engagement@fda.hhs.gov